TAC1 and atrial fibrillation: Digoxin, a specific NKA inhibitor, is used to treat patients with atrial fibrillation or severe heart failure (Bavendiek et al. 2017) to improve cardiac output (Levi et al. 1994), but potentially impairs exercise performance due to NKA inhibition and ensuing high [K+].